Large Pharma Integrates NextDocs eTMF, CTMS and Investigator Portal
NextDocs announced that leading pharmaceutical and biologics companies implemented late last year the NextDocs clinical solution suite
NextDocs announced that leading pharmaceutical and biologics companies implemented late last year the NextDocs clinical solution suite across more than 200 clinical trials to manage regulated content and compliance, and bring together clinical trial constituencies onto a single management system.
The pharma sponsor initially deployed the NextDocs eTMF solution over two years ago to manage clinical trial documents. In 2013, the company expanded the deployment to include Clinical Research Organization (CRO) access. Subsequently, the company deployed the NextDocs Trial Exchange (TrX) investigator portal solution to provide external access to a user community of over 30,000 investigators across more than 10,000 trial sites.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
